Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
CC transcript
Director departure
Inv. presentation
Orexigen Therapeutics, Inc. (OREXQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/23/2019 8-K Bankruptcy or Receivership, Financial Statements and Exhibits
Docs: "Debtor's Modified Amended Plan of Liquidation"
04/02/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report",
"Monthly Operating Report"
03/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report",
"Monthly Operating Report"
02/05/2019 8-K Quarterly results
12/14/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report",
"Monthly Operating Report"
12/04/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report",
"Monthly Operating Report"
10/31/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report",
"Monthly Operating Report"
10/01/2018 8-K Quarterly results
07/31/2018 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 26, 2018 OREXIGEN THERAPEUTICS, INC. Delaware 001-33415 65-1178822 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 Registrant's telephone number, including area code: 875-8600",
"Amendment to the Asset Purchase Agreement, by and between Orexigen Therapeutics, Inc. and Nalpropion Pharmaceuticals, Inc",
"Monthly Operating Report"
07/05/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report",
"Monthly Operating Report"
06/22/2018 8-K Other Events
Docs: "FORM 8-K"
06/06/2018 8-K Quarterly results
04/23/2018 8-K Acquisition/merger/asset purchase announced
Docs: "FORM 8-K",
"Asset Purchase Agreement, by and between Orexigen Therapeutics, Inc. and Nalpropion Pharmaceuticals, Inc. (Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K and are not filed herewith. The registrant hereby agrees to furnish a copy of any omitted schedule or exhibits to the U.S. Securities and Exchange Commission upon request.)",
"Key Employee Incentive Plan",
"Bidding Procedures Order, filed with the United States Bankruptcy Court for the District of Delaware on April 23, 2018",
"Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company"
04/13/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Initial Monthly Operating Report",
"Initial Monthly Operating Report"
04/03/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/02/2018 8-K Other Events
03/23/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Instrument of Resignation, Appointment and Acceptance, by and among Orexigen Therapeutics, Inc., Wilmington Savings Fund Society, FSB and U.S. Bank National Association, relating to the 2.75% Convertible Exchange Senior Notes due 2020"
03/15/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 12, 2018 OREXIGEN THERAPEUTICS, INC. Delaware 001-33415 65-1178822 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 Registrant's telephone number, including area code: 875-8600"
03/12/2018 8-K Filed for Chapter 11
Docs: "FORM 8-K",
"Debtor in Possession Credit and Security Agreement, by and between the Company, Wilmington Trust, National Association, as administrative agent, and certain lenders",
"OREXIGEN THERAPEUTICS, INC. PLANS FOR NEAR-TERM SALE USING STRUCTURED PROCESS THROUGH CHAPTER 11 OF U.S. BANKRUPTCY CODE Bidding Process and Auction Projected to Conclude in May 2018"
02/28/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/09/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Security Ownership of Certain Beneficial Owners and Management as of December 31, 2017",
"Security Ownership of Certain Beneficial Owners and Management as of December 31, 2017"
01/19/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Slide Presentation",
"Slide Presentation"
01/08/2018 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Slide Presentation"
12/29/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/13/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 13, 2017 OREXIGEN THERAPEUTICS, INC. Delaware 001-33415 65-1178822 3344 N. Torrey Pines Court, Suite 200 La Jolla, California 92037 Registrant's Telephone Number, Including Area Code: 875-8600 Not Applicable",
"Orexigen Therapeutics Announces Third Quarter 2017 Financial Results"
10/18/2017 8-K Quarterly results
10/16/2017 8-K Quarterly results
10/13/2017 8-K Quarterly results
09/26/2017 8-K Quarterly results
08/18/2017 8-K/A Quarterly results
08/08/2017 8-K Quarterly results
Docs: "Orexigen Therapeutics Announces Second Quarter 2017 Financial Results Contrave achieves all-time high for quarterly U.S. net sales, growing 69% year-over-year"
07/14/2017 8-K Form 8-K - Current report:
06/30/2017 8-K Form 8-K - Current report
05/09/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy